Cap

Zacks Small Cap Analysis – CTSO: CytoSorbents Potential for Excessive Margin Income Progress Helps Worth Goal of $4.00 – Go Well being Professional

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT CytoSorbents (NASDAQ:CTSO) reported 2nd quarter 2024 outcomes on August thirteenth and the outcomes have been principally above our expectations. For the 2nd quarter of 2024, complete revenues elevated roughly 5.0% to $9.9 million. Complete product gross sales have been $8.8 million, a rise of … Read more

Zacks Small Cap Analysis – VNRX: Nu.Q Vet Check is now obtainable in 17 international locations. Value slicing continues in a plan to be money move impartial in 2025. Administration centered on signing licensing offers for Seize-PCR (human most cancers detection technique) and Nu.Q NET for sepsis. $7.0 million financing accomplished. – Go Well being Professional

by
Zacks Small Cap Analysis – VNRX: Nu.Q Vet Check is now obtainable in 17 international locations. Value slicing continues in a plan to be money move impartial in 2025. Administration centered on signing licensing offers for Seize-PCR (human most cancers detection technique) and Nu.Q NET for sepsis. .0 million financing accomplished. – Go Well being Professional

By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT SIGNIFICANT OPERATIONAL UPDATES Administration is implementing a important value slicing program with the aim of making certain that Volition (NYSE:VNRX) is money move impartial in 2025. Value reductions taken throughout 1H 2024 resulted in a 15.9% decline in working bills. Value discount measures have … Read more

Zacks Small Cap Analysis – MNOV: Part 3 ALS Readout in 2025… – Go Well being Professional

by

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Enterprise Replace Part 3 ALS Trial Ongoing MediciNova, Inc. (NASDAQ:MNOV) is at the moment evaluating MN-166 (ibudilast) in a Part 3 scientific trial for amyotrophic lateral sclerosis (ALS). The trial initiated in 2019 and, if profitable, outcomes from this trial are anticipated to assist … Read more

Zacks Small Cap Analysis – ORMP: Steadiness Sheet Sturdy, Potential Advantages of Investments, JVs, Buybacks – Go Well being Professional

by

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Stable money & equivalents place as former CFO resumes position… Oramed Prescription drugs (NASDAQ:ORMP) has named its former Chief Monetary Officer to the CFO place once more. In June 2024, the corporate named Avraham Gabay as CFO, Secretary and Treasurer to interchange former CFO David … Read more

Zacks Small Cap Analysis – HTCR: HeartCore Stories 2nd Quarter 2024 Outcomes and Updates Funding Neighborhood on Present Operations – Go Well being Professional

by

By Thomas Kerr, CFA NASDAQ:HTCR READ THE FULL HTCR RESEARCH REPORT On August 14, 2024, HeartCore (NASDAQ:HTCR) reported 2nd quarter 2024 monetary outcomes which confirmed revenues beneath expectations regardless of 20% natural development within the core software program enterprise. Revenues within the quarter have been $4.1 million in comparison with $5.1 million within the 2nd … Read more

x